排序方式: 共有82条查询结果,搜索用时 15 毫秒
41.
42.
Impact of branched‐chain amino acid supplementation on survival in patients with advanced hepatocellular carcinoma treated with sorafenib: A multicenter retrospective cohort study
下载免费PDF全文
![点击此处可从《Hepatology research》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Kazuho Imanaka Kazuyoshi Ohkawa Tomohide Tatsumi Kazuhiro Katayama Atsuo Inoue Yasuharu Imai Masahide Oshita Sadaharu Iio Eiji Mita Hiroyuki Fukui Akira Yamada Fumihiko Nakanishi Masami Inada Yoshinori Doi Kunio Suzuki Akira Kaneko Shigeru Marubashi Yuri Ito Keisuke Fukui Ryotaro Sakamori Takayuki Yakushijin Naoki Hiramatsu Norio Hayashi Tetsuo Takehara the Osaka Liver Forum 《Hepatology research》2016,46(10):1002-1010
43.
Yuki Tahata Naoki Hiramatsu Tsugiko Oze Naoki Morishita Naoki Harada Ryoko Yamada Takayuki Yakushijin Eiji Mita Hideki Hagiwara Yukinori Yamada Toshifumi Ito Taizo Hijioka Masami Inada Kazuhiro Katayama Shinji Tamura Harumasa Yoshihara Atsuo Inoue Yasuharu Imai Keiko Irishio Michio Kato Hayato Hikita Ryotaro Sakamori Takuya Miyagi Yuichi Yoshida Tomohide Tatsumi Toshimitsu Hamasaki Norio Hayashi Tetsuo Takehara 《Journal of gastroenterology》2016,51(3):252-259
44.
Katsuhiro Masago Shiro Fujita Tadashi Mio Yosuke Togashi Young Hak Kim Yukimasa Hatachi Akiko Fukuhara Kaoru Irisa Yuichi Sakamori Michiaki Mishima 《Medical oncology (Northwood, London, England)》2011,28(1):351-356
The aims of this study are to: (a) confirm the prognostic significance of the procoagulant molecules D dimer, thrombin–antithrombin
complex (TAT), and plasmin-α2–plasmin inhibitor complex (PIC); (b) to evaluate hemostatic activation in patients with advanced
non-small cell lung cancer (NSCLC); and (c) to delineate the relationships between markers of hemostasis and other clinical
characteristics. In this study, a low PIC/TAT ratio and poor PS were significant independent negative prognostic factors for
survival in patients with advanced NSCLC. The PIC/TAT ratio may become a surrogate marker for treatment with anticoagulants
in the future. 相似文献
45.
Seiya Kato Ryotaro Sakamori Ryoko Yamada Kazuhiro Murai Teppei Yoshioka Yuki Tahata Minoru Shigekawa Takahiro Kodama Hayato Hikita Hidenari Hongyo Yusuke Ono Hiroki Higashihara Tomohide Tatsumi Tetsuo Takehara 《Internal medicine (Tokyo, Japan)》2021,60(16):2617
We herein report the first case of interventional radiology for a left gastric vein aneurysm with a gastrorenal shunt. The etiology of the aneurysm was considered secondary to portal hypertension and liver cirrhosis due to hepatitis B virus infection. As the aneurysm was asymptomatic but had a tendency to expand, we successfully performed coil embolization for the aneurysm through a gastrorenal shunt. 相似文献
46.
47.
Togashi Y Kim YH Masago K Sakamori Y Okuda C Mio T Mishima M 《Japanese journal of clinical oncology》2011,41(4):582-585
The prognosis of small-cell lung cancer remains poor and it is speculated that small-cell lung cancer patients with end-stage renal failure undergoing hemodialysis have a poorer prognosis. In this article, we present a Japanese woman with extensive small-cell lung cancer with end-stage renal failure undergoing hemodialysis who received multiple courses of chemotherapy. Although she achieved long-term survival of more than 2 years, the last-line chemotherapy, consisting of irinotecan, induced grade 4 febrile neutropenia and her performance status deteriorated even with a reduced dose according to the analysis of UDP-glucuronosyltransferase 1A1. We also conducted a pharmacokinetic analysis of irinotecan, the resulting values of which were much higher than in previous reports. Although further studies are needed, chemotherapy for small-cell lung cancer patients should not be withheld just because they are undergoing hemodialysis; however, chemotherapy should be performed more carefully because more severe toxicities can occur than expected. 相似文献
48.
Masago K Fujita S Togashi Y Kim YH Hatachi Y Fukuhara A Nagai H Irisa K Sakamori Y Mio T Mishima M 《Oncology reports》2011,26(4):795-803
This study of patients with advanced non-squamous non-small cell lung cancer (NSCLC) evaluated epidermal growth factor receptor (EGFR) mutation status and two serum markers, serum insulin-like growth factor 1 (IGF1) and IGF binding protein 3 (IGFBP3), for their associations to response to gefitinib therapy and for their prognostic impact. An immunoradiometric assay determined levels of IGF1 and IGFBP3 in serum from 68 patients with advanced non-squamous NSCLC. The peptic nucleic acid locked nucleic acid clamp method determined their EGFR somatic mutation status. We evaluated the relationship between each independent clinicopathological variable and the response to gefitinib therapy and the risk factors associated with prognosis. Having IGF1-positive serum as determined by the 75th percentile and having wild-type EGFR were both independent negative predictive factors for geftinib treatment by multivariate logistic regression model analysis. Both having serum positive for IGF1 as determined by the 25th percentile and having wild-type EGFR were significant independent negative prognostic factors for survival based on multivariate analysis. We demonstrated that having IGF1-positive serum predicts a negative response to gefitinib therapy independent of EGFR mutational status. We also demonstrated that both IGF1-positive serum and wild-type EGFR were independent poor prognostic factors in patients with non-squamous NSCLC who received gefitinib therapy. 相似文献
49.
Togashi Y Kim YH Masago K Tamai K Sakamori Y Mio T Mishima M 《International journal of clinical oncology / Japan Society of Clinical Oncology》2011,16(4):444-446
Internal jugular vein thrombosis is much less common than deep venous thrombosis of lower limbs and is generally caused by
an indwelling venous catheter or otological infection. Several cases of internal jugular vein thrombosis associated with malignancy
have been also reported. Bevacizumab, a monoclonal neutralizing antibody against vascular endothelial growth factor, has shown
benefits in the treatment of many types of malignancy and its use is increasing. Serious adverse effects, however, are associated
with the use of bevacizumab, including venous thromboembolism. In this article, we present a rare case of non-small cell lung
cancer complicated by pulmonary embolism due to internal jugular vein thrombosis associated with bevacizumab. 相似文献
50.